Stockscreener 앱 받기
1.32
4.35%
-0.06
전일 마감가:
$1.38
열려 있는:
$1.35
하루 거래량:
137.95K
Relative Volume:
0.55
시가총액:
$76.51M
수익:
$2.91M
순이익/손실:
$-220.40M
주가수익비율:
-0.3626
EPS:
-3.64
순현금흐름:
$-176.15M
1주 성능:
+8.20%
1개월 성능:
+4.76%
6개월 성능:
-92.16%
1년 성능:
-82.75%
1일 변동 폭
$1.31
$1.395
1주일 범위
$1.22
$1.47
52주 변동 폭
$0.92
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
명칭
Igm Biosciences Inc
전화
650-965-7873
주소
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
IGMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
1.32 | 76.51M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-01-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-01-10 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2025-01-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-01-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-10-01 | 다운그레이드 | Truist | Buy → Hold |
| 2024-02-09 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-11-09 | 재개 | Jefferies | Buy |
| 2022-10-17 | 개시 | JP Morgan | Neutral |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2021-12-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-05 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-08-26 | 개시 | Morgan Stanley | Overweight |
| 2021-01-29 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-07-17 | 개시 | Robert W. Baird | Outperform |
| 2020-07-01 | 개시 | H.C. Wainwright | Buy |
| 2020-05-28 | 개시 | SunTrust | Buy |
| 2020-04-22 | 개시 | Wedbush | Outperform |
| 2019-10-14 | 개시 | Guggenheim | Buy |
| 2019-10-14 | 개시 | Jefferies | Buy |
| 2019-10-14 | 개시 | Piper Jaffray | Overweight |
| 2019-10-14 | 개시 | Stifel | Buy |
모두보기
Igm Biosciences Inc 주식(IGMS)의 최신 뉴스
Igm biosciences principal accounting officer sells $1,907 in stock - MSN
Fierce Biotech Layoff Tracker 2025: Mural lays off 90%; Tempest cuts 80% of roles - Fierce Biotech
IGMS stock touches 52-week low at $1 amid sharp annual decline - Investing.com
IGMS stock touches 52-week low at $1 amid sharp annual decline By Investing.com - Investing.com South Africa
IGM Bio stock slips as Bank of America downgrades (IGMS:NASDAQ) - Seeking Alpha
Short Interest in IGM Biosciences, Inc. (NASDAQ:IGMS) Decreases By 19.3% - MarketBeat
IGMS STOCK ALERT: Levi & Korsinsky Notifies IGM Biosciences, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
IGMS stock plunges to 52-week low at $1.14 amid market challenges - Investing.com Australia
IGMS stock plunges to 52-week low at $1.14 amid market challenges By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Buys 9,441 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9%What's Next? - MarketBeat
IGM Biosciences stock plunges to 52-week low of $1.59 - MSN
IGM Biosciences, Inc. (NASDAQ:IGMS) Given Average Rating of "Reduce" by Brokerages - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $5.50 Consensus PT from Brokerages - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9% – Here’s Why - Defense World
Sanofi Advances Immunology Ambitions With Dren Deal - insights.citeline.com
IGM Biosciences CEO Mary Beth Harler sells $9,014 in stock By Investing.com - Investing.com Australia
IGM Biosciences CFO Tahir Misbah sells shares worth $9,014 By Investing.com - Investing.com South Africa
IGM Biosciences chief business officer sells $5,549 in stock By Investing.com - Investing.com South Africa
IGM Biosciences CEO Mary Beth Harler sells $9,014 in stock - Investing.com India
IGM Biosciences chief business officer sells $5,549 in stock - Investing.com India
IGM Biosciences CFO Tahir Misbah sells shares worth $9,014 - Investing.com India
Igm biosciences officer sells shares worth $2,092 - Investing.com India
Igm biosciences officer sells shares worth $2,092 By Investing.com - Investing.com Australia
IGM Biosciences stock plunges to 52-week low at $1.17 By Investing.com - Investing.com Australia
IGM Biosciences stock plunges to 52-week low at $1.17 - Investing.com India
IGM Biosciences Faces Uncertainty Amid Cash Preservation and Restructuring Efforts - TipRanks
IGM Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
IGM Biosciences Inc. (IGMS) reports earnings - qz.com
Contrasting IGM Biosciences (NASDAQ:IGMS) and Gyre Therapeutics (NASDAQ:GYRE) - Defense World
IGM Biosciences stock plunges to 52-week low of $1.25 By Investing.com - Investing.com Australia
IGM Biosciences stock plunges to 52-week low of $1.25 - Investing.com India
IGM Biosciences Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
IGM Biosciences (IGMS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - MSN
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of “Reduce” from Brokerages - Defense World
Igm Biosciences Inc (IGMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):